Orexo AB (publ) (ORX.ST)
SEK 14.36
(2.57%)
SEK 14.36
(2.57%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 727.7 Million SEK | -20.48% |
| 2022 | 915.1 Million SEK | -0.97% |
| 2021 | 924.1 Million SEK | 37.03% |
| 2020 | 674.4 Million SEK | -15.14% |
| 2019 | 794.7 Million SEK | -1.96% |
| 2018 | 810.6 Million SEK | 20.12% |
| 2017 | 674.8 Million SEK | -4.76% |
| 2016 | 708.5 Million SEK | -5.51% |
| 2015 | 749.84 Million SEK | -2.73% |
| 2014 | 770.86 Million SEK | 26.19% |
| 2013 | 610.87 Million SEK | 110.24% |
| 2012 | 290.56 Million SEK | 23.64% |
| 2011 | 235 Million SEK | -3.87% |
| 2010 | 244.45 Million SEK | 142.82% |
| 2009 | 100.67 Million SEK | -23.87% |
| 2008 | 132.24 Million SEK | 1.24% |
| 2007 | 130.62 Million SEK | 135.01% |
| 2006 | 55.58 Million SEK | 71.54% |
| 2005 | 32.4 Million SEK | 21.9% |
| 2004 | 26.58 Million SEK | 186.74% |
| 2003 | 9.27 Million SEK | 19.91% |
| 2002 | 7.73 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 768.5 Million SEK | 5.61% |
| 2024 Q2 | 749.1 Million SEK | -2.52% |
| 2024 Q3 | 724.2 Million SEK | -3.32% |
| 2023 FY | 727.7 Million SEK | -20.48% |
| 2023 Q1 | 820.2 Million SEK | -10.37% |
| 2023 Q3 | 777 Million SEK | -3.25% |
| 2023 Q4 | 727.7 Million SEK | -6.34% |
| 2023 Q2 | 803.1 Million SEK | -2.08% |
| 2022 Q1 | 876.2 Million SEK | -5.18% |
| 2022 FY | 915.1 Million SEK | -0.97% |
| 2022 Q4 | 915.1 Million SEK | 1.1% |
| 2022 Q2 | 962.1 Million SEK | 9.8% |
| 2022 Q3 | 905.1 Million SEK | -5.92% |
| 2021 Q2 | 885.5 Million SEK | -1.47% |
| 2021 Q1 | 898.7 Million SEK | 33.26% |
| 2021 FY | 924.1 Million SEK | 37.03% |
| 2021 Q4 | 924.1 Million SEK | 2.63% |
| 2021 Q3 | 900.4 Million SEK | 1.68% |
| 2020 Q3 | 708.8 Million SEK | -2.57% |
| 2020 Q4 | 674.4 Million SEK | -4.85% |
| 2020 Q1 | 775.1 Million SEK | -2.47% |
| 2020 Q2 | 727.5 Million SEK | -6.14% |
| 2020 FY | 674.4 Million SEK | -15.14% |
| 2019 Q1 | 870.8 Million SEK | 7.43% |
| 2019 FY | 794.7 Million SEK | -1.96% |
| 2019 Q4 | 794.7 Million SEK | -9.03% |
| 2019 Q3 | 873.6 Million SEK | -1.53% |
| 2019 Q2 | 887.2 Million SEK | 1.88% |
| 2018 Q3 | 783.9 Million SEK | -3.48% |
| 2018 Q1 | 730 Million SEK | 8.18% |
| 2018 Q2 | 812.2 Million SEK | 11.26% |
| 2018 FY | 810.6 Million SEK | 20.12% |
| 2018 Q4 | 810.6 Million SEK | 3.41% |
| 2017 Q4 | 674.8 Million SEK | -7.98% |
| 2017 Q3 | 733.3 Million SEK | 4.7% |
| 2017 Q2 | 700.4 Million SEK | 5.67% |
| 2017 FY | 674.8 Million SEK | -4.76% |
| 2017 Q1 | 662.8 Million SEK | -6.45% |
| 2016 FY | 708.5 Million SEK | -5.51% |
| 2016 Q4 | 708.5 Million SEK | -11.63% |
| 2016 Q3 | 801.7 Million SEK | -5.12% |
| 2016 Q2 | 845 Million SEK | 7.02% |
| 2016 Q1 | 789.6 Million SEK | 5.3% |
| 2015 Q4 | 749.84 Million SEK | -4.45% |
| 2015 Q2 | 813.7 Million SEK | 1.71% |
| 2015 Q1 | 800 Million SEK | 3.78% |
| 2015 FY | 749.84 Million SEK | -2.73% |
| 2015 Q3 | 784.8 Million SEK | -3.55% |
| 2014 Q2 | 824.6 Million SEK | 37.41% |
| 2014 Q1 | 600.1 Million SEK | -1.76% |
| 2014 Q3 | 772.4 Million SEK | -6.33% |
| 2014 Q4 | 770.86 Million SEK | -0.2% |
| 2014 FY | 770.86 Million SEK | 26.19% |
| 2013 Q2 | 489.2 Million SEK | 83.98% |
| 2013 FY | 610.87 Million SEK | 110.24% |
| 2013 Q4 | 610.87 Million SEK | 35.3% |
| 2013 Q3 | 451.5 Million SEK | -7.71% |
| 2013 Q1 | 265.9 Million SEK | -8.49% |
| 2012 Q4 | 290.56 Million SEK | -18.4% |
| 2012 Q3 | 356.1 Million SEK | -11.88% |
| 2012 FY | 290.56 Million SEK | 23.64% |
| 2012 Q1 | 191.9 Million SEK | -18.34% |
| 2012 Q2 | 404.1 Million SEK | 110.58% |
| 2011 FY | 235 Million SEK | -3.87% |
| 2011 Q4 | 235 Million SEK | 1.44% |
| 2011 Q3 | 231.65 Million SEK | -1.53% |
| 2011 Q2 | 235.26 Million SEK | -0.45% |
| 2011 Q1 | 236.32 Million SEK | -3.32% |
| 2010 Q3 | 242.06 Million SEK | -9.24% |
| 2010 Q4 | 244.45 Million SEK | 0.99% |
| 2010 FY | 244.45 Million SEK | 142.82% |
| 2010 Q1 | 78.63 Million SEK | -21.89% |
| 2010 Q2 | 266.7 Million SEK | 239.16% |
| 2009 FY | 100.67 Million SEK | -23.87% |
| 2009 Q3 | 81.79 Million SEK | 0.0% |
| 2009 Q4 | 100.67 Million SEK | 23.09% |
| 2008 Q4 | 132.24 Million SEK | 0.0% |
| 2008 FY | 132.24 Million SEK | 1.24% |
| 2007 FY | 130.62 Million SEK | 135.01% |
| 2006 FY | 55.58 Million SEK | 71.54% |
| 2005 FY | 32.4 Million SEK | 21.9% |
| 2004 FY | 26.58 Million SEK | 186.74% |
| 2003 FY | 9.27 Million SEK | 19.91% |
| 2002 FY | 7.73 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AcuCort AB | 10.97 Million SEK | -6530.524% |
| AlzeCure Pharma AB (publ) | 8.22 Million SEK | -8745.266% |
| BioGaia AB (publ) | 302.84 Million SEK | -140.288% |
| Enzymatica AB (publ) | 49.3 Million SEK | -1376.005% |
| Enorama Pharma AB (publ) | 14.84 Million SEK | -4801.327% |
| Gabather AB (publ) | 6.87 Million SEK | -10480.11% |
| Klaria Pharma Holding AB (publ.) | 31.98 Million SEK | -2175.058% |
| Moberg Pharma AB (publ) | 24 Million SEK | -2931.199% |
| Nanexa AB (publ) | 36.42 Million SEK | -1897.694% |
| Newbury Pharmaceuticals AB (publ) | 38.95 Million SEK | -1768.101% |
| ODI Pharma AB | 10.05 Million SEK | -7135.271% |
| Probi AB (publ) | 181.31 Million SEK | -301.339% |
| Swedencare AB (publ) | 2.31 Billion SEK | 68.57% |
| Swedish Orphan Biovitrum AB (publ) | 40.16 Billion SEK | 98.188% |
| Toleranzia AB | 6.9 Million SEK | -10432.639% |
| Vivesto AB | 30.45 Million SEK | -2289.662% |